ProKidney

Yahoo Finance • 8 days ago

ProKidney Expects Phase 3 PROACT 1 Pivotal Trial Results For Rilparencel In Q2 2027

(RTTNews) - ProKidney Corp. (PROK), a clinical-stage cell therapy company focused on chronic kidney disease or CKD, reported financial results for the full year 2025 and provided business highlights about its lead investigational candidate... Full story

Yahoo Finance • 23 days ago

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment... Full story

Yahoo Finance • last month

3 Promising Penny Stocks With At Least $600M Market Cap

As U.S. stock indexes have started February on a high note, with the Dow Jones Industrial Average and S&P 500 showing impressive gains, investors are closely watching for opportunities in various market segments. Penny stocks, while often... Full story

Yahoo Finance • 4 months ago

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the patients required for the Phase 3 REGE... Full story

Yahoo Finance • 5 months ago

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025

In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidney injection with rilparencel resulted... Full story

Yahoo Finance • 5 months ago

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced th... Full story

Yahoo Finance • 5 months ago

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced th... Full story

Yahoo Finance • 6 months ago

ProKidney Corp (PROK) Touts Reparencel Therapy for Growth

ProKidney Corp (NASDAQ:PROK) is one of the best healthcare penny stocks to buy now. On September 8, at the Morgan Stanley 23rd Annual Global Healthcare Conference, the company reiterated its focus on the promising cell therapy, Reparencel.... Full story

Yahoo Finance • 6 months ago

Which stocks are experiencing notable movement on Friday?

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. [topmovers] GAINERS TICKER CHANGE COMMENT GCTK [ht... Full story

Yahoo Finance • 6 months ago

What's going on in today's session

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT VNCE [https://www.chartmill.com/stock/quote/VNCE/profile] 113.0% VINCE H... Full story

Yahoo Finance • 7 months ago

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced th... Full story

Yahoo Finance • 7 months ago

ProKidney Corp (NASDAQ:PROK) Reports Mixed Q2 2025 Results with Regulatory Progress and Narrower Loss

PROKIDNEY CORP. (NASDAQ:PROK [https://www.chartmill.com/stock/quote/PROK]) REPORTS Q2 2025 RESULTS: MIXED FINANCIALS AND REGULATORY PROGRESS ProKidney Corp., a clinical-stage biotechnology company focused on chronic kidney disease (CKD) t... Full story

Yahoo Finance • 7 months ago

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced CKD; FDA also confi... Full story

Yahoo Finance • 8 months ago

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement

ProKidney Corp. (NASDAQ:PROK) is one of the best high-return penny stocks to buy now. On July 16, the company confirmed the completion of its corporate domestication from the Cayman Islands to the state of Delaware. The change of jurisdict... Full story

Yahoo Finance • 8 months ago

ProKidney Secures FDA Alignment On Accelerated Approval Pathway For Rilparencel

(RTTNews) - ProKidney Corp. (PROK) Tuesday said it has secured alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for rilparencel. The FDA confirmed that the slope of estimated glomerular filtra... Full story

Yahoo Finance • 8 months ago

ProKidney stock falls after FDA alignment on rilparencel approval pathway

Investing.com -- ProKidney Corp. (NASDAQ:PROK) stock initially fell 11% in premarket trading after the company announced alignment with the FDA on the accelerated approval pathway for its kidney disease treatment rilparencel. Shares late... Full story

Yahoo Finance • 8 months ago

FDA confirms eGFR slope as acceptable endpoint for rilparencel approval

WINSTON-SALEM, N.C. - ProKidney Corp. (NASDAQ:PROK), a biotechnology company whose shares have surged over 130% in the past six months according to InvestingPro data, announced Tuesday that the U.S. Food and Drug Administration has confirm... Full story

Yahoo Finance • 8 months ago

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated a... Full story

Yahoo Finance • 9 months ago

Prokidney (PROK) chief regulatory officer Weber sells $312k in stock

Prokidney Corp. (NASDAQ:PROK) Chief Regulatory Officer Darin J. Weber, sold 103,480 shares of Class A Common Stock on July 8, 2025, for $3.02, totaling $312,509. The stock, currently trading at $4.34, has seen remarkable gains with a 544%... Full story

Yahoo Finance • 9 months ago

ProKidney stock surges after Citi raises price target to $9

Investing.com -- ProKidney Corp. (NASDAQ:PROK) stock surged 65% in pre-market trading on Wednesday, building on Tuesday’s massive 515% gain following positive clinical trial data. The latest jump came after Citi analysts raised their pr... Full story